Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas

References

• Zinzani P L, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardiani L, Mazza P, Marra R, Ronconi F, Lauta V M, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. Journal of Clinical Oncology 2000; 18: 773–779
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau J L, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Group d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1996; 14: 514–519
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pulsoni A, Pernotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta V M, Guardigli L, Gentilini P, Tucci A, Molinari A L, Gobbi M, Falini B, Fattori P P, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. Journal of Clinical Oncology 2004; 22: 2654–2661
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Annals of Oncology 1997; 8: 379–383
   PubMed Web of Science ®Google Scholar
• Boogaerts M A, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani P L, Binet J L, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 2001; 19: 4252–4258
   PubMed Web of Science ®Google Scholar
• Rossi J F, Van Hoof A, de Boeck K, Johnson S A, Bron D, Foussard C, Lister T A, Berthou C, Kramer M H, Littlewood T J, Marcus R E, Deconinck E, Montillo M, Guibon O, Tollerfield S M. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 2004; 22: 1260–1267
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Harris N, Jaffe E, Stein H, Banks P M, Chan J K, Cleary M L, Delsol G, De Wolf-Peeters C, Falini B, Gatter K C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, Lister T A, Vose J M, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris N L, Armitage J O, Carter W, Hoppe R, Canellos G P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology 1999; 17: 1244–1253, NCI Sponsored International Working Group
   PubMed Web of Science ®Google Scholar
• Klasa R J, Meyer R M, Shustik C, Sawka C A, Smith A, Guevin R, Maksymiuk A, Rubinger M, Samosh M, Laplante S, Grenier J F. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. Journal of Clinical Oncology 2002; 20: 4649–4654
   PubMed Web of Science ®Google Scholar
• Hochster H S, Oken M M, Winter J N, Gordon L I, Raphael B G, Bennett J M, Cassileth P A. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up – a report from the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2000; 18: 987–994
   PubMed Web of Science ®Google Scholar
• Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu A M, Truini M, Rubagotti A, Chisesi T, Vimercati R, Rossi E, Sertoli M R, Mattei D, Marino G, Gobbi M. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282–286
   PubMed Web of Science ®Google Scholar